Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.

< BACK TO ARCHIVE


Papers: 4 Jun 2022 - 10 Jun 2022


Human Studies


2022 Jun 01


JAMA Netw Open


http://www.ncbi.nlm.nih.gov/pubmed/35675076?dopt=Abstract


5


6

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.

Authors

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
Lipton RB, Pozo-Rosich P, Blumenfeld AM, Dodick DW, McAllister P, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM
JAMA Netw Open. 2022 Jun 01; 5(6):e2215499.
PMID: 35675076.

Abstract

Some patients with migraine, particularly those in primary care, require effective, well-tolerated, migraine-specific oral preventive treatments.
Read This Paper